Sigma-Aldrich (Nasdaq: SIAL) Reports 9.4% Increase in Q3 2009 Diluted EPS; Sales Performance Improved in Q3 2009 Over Earlier 2009 Quarters. Full Year 2009 Diluted EPS Expected to Exceed $2.70.

Thursday, October 22, 2009 General News
Email Print This Page Comment bookmark
Font : A-A+

ST. LOUIS, Oct. 22 /PRNewswire-FirstCall/ --

HIGHLIGHTS (all percentages are to comparable periods in 2008):


2009 Results

  • Q3 2009 reported sales declined by 1.3%; excluding the impact of currency, sales grew organically by 2.3% from a year ago, driven by improved sales of Research Biotech products and fine chemicals (SAFC).
  • Strong pretax profit margin and favorable tax rate raise Q3 2009 diluted EPS by 9.4% to $0.70.  Diluted EPS would have been $0.80 without a $0.10 adverse impact from currency exchange rates.
  • Q3 2009 free cash flow of $115 million drives year-to-date total to $274 million, an 17% increase over the first nine months of 2008.


  • Sales for the full year 2009 are expected to meet the Company's previously forecast organic growth in low single digits.  Currency is expected to reduce otherwise reportable 2009 growth by approximately 4% if exchange rates remain near September 30, 2009 levels.
  • Full year 2009 diluted EPS is expected to exceed $2.70.
  • Free cash flow is expected to exceed $325 million for 2009.


Commenting on third quarter 2009 performance, Chairman, President and CEO Jai Nagarkatti said:  "We are very pleased with our improved sales performance in the third quarter of 2009 in continued challenging economic conditions. And we're particularly pleased with the $0.70 of diluted EPS delivered for the third quarter of 2009, our best quarterly performance this year.  We continued our tradition of adding new and innovative products and technologies to support life science research.  We were pleased to announce the expansion of our agreement with Sangamo BioSciences to use zinc finger technology in the production of therapeutic proteins and in commercial areas of transgenics.  A new partnership with the Michael J. Fox Foundation to create the first Parkinson's disease model in rats has generated much excitement in the research community.  The recent acquisition of ChemNavigator offers the scientific community a powerful cheminformatics platform that streamlines the design and procurement of chemical compound libraries."

Nagarkatti continued, "We've reaffirmed our sales and profit expectations for all of 2009, continuing to believe that we can achieve above-market rate organic sales growth in the low single digits and deliver diluted EPS slightly in excess of $2.70, reflecting a gain over last year's $2.65. We expect a small contribution from supplying key components to H1N1 vaccine manufacturing customers and from a slight increase in government research funding.  We plan to add new sales growth and profitability enhancing activities that together with better economic conditions should improve our growth in 2010. But we expect the market recovery to be slow. With that in mind, we have identified additional initiatives to drive our core chemistry and biochemistry sales at above market growth rates.  We also plan to increase our share in the faster growing biotech and analytical product areas."  


Reported sales for the third quarter of 2009 were $534 million, a decline of 1.3% from the third quarter of 2008.  Without reflecting an unfavorable currency impact that reduced reported sales by 3.6%, sales would have shown organic growth of 2.3%. For the nine months ended September 30, 2009, reported sales declined by 6.8% from the first nine months of 2008 while overall organic sales were largely consistent with the prior year level.  Organic sales for the Company's Research business grew 1.4% and 1.9% for the third quarter and first nine months of 2009, respectively.  Organic sales for SAFC increased by 4.8% for the third quarter of 2009 as sales of H1N1 vaccine adjuvants to pharma companies and shipments of industrial media and other previously booked orders drove sales for this unit to a quarterly high for 2009. Year-to-date organic sales for SAFC declined by 2.8% from the comparable prior year level.   Quarterly and year-to-date comparisons and a reconciliation of reported to adjusted (organic) sales growth are on page 8.

The operating income margin in the third quarter 2009 of 22.9% of sales reflects a modest decline from levels in 2008's third quarter and 2009's first half resulting from unfavorable currency and a slight unfavorable product mix resulting from higher SAFC sales.  The Company continued to take proactive steps to accelerate benefits from its global supply chain activities and to lower S,G&A costs in an effort to offset the adverse currency impact on earnings it has experienced in the first nine months of 2009.  

Free cash flow (defined on page 7) for the third quarter of 2009 was $115 million, resulting in free cash provided in the first nine months of 2009 of $274 million. A reconciliation of net cash provided by operating activities to free cash flow is on page 9.

Other highlights in the third quarter from global sales growth initiatives and profit enhancement activities include:

  • Continued increase in sales of research products through the Company's award winning web site to 46% of worldwide Research-based sales in the third quarter of 2009, up from 45% in Q2 2009.
  • Continued strength in International markets (Canada, Asia Pacific and Latin America) which experienced an 8% organic growth in research-based sales.  Sales in the Company's focus markets of China, India and Brazil collectively grew by 30% organically in the quarter over the prior year level.
  • SAFC's booked orders for future delivery at September 30, 2009 remained strong.
  • $5 million of supply chain process improvement benefits, boosting the year-to-date result to $18 million, in excess of original plans to help offset the currency headwind.


  • Management reaffirmed its full year 2009 organic sales growth expectation in a low single digit range.  This sales growth is expected to be driven by the Company's global sales initiatives of its "lab essential" products, growth in the faster growing research products for cell biology and analytical chemistry, and the SAFC Bioscience offering of industrial media. On the other hand, demand from the pharmaceutical, chemical and hi-tech industries is expected to continue to reflect the uncertainty in these markets. Due to the lack of clarity on allocations and timing, the current outlook does not include a significant amount of sales from stimulus and other funding by the U.S. and other world governments.  Currency exchange rates are expected to reduce otherwise reportable growth in 2009 by approximately 4% if exchange rates remain at current levels.
  • The negative impact of currency on diluted EPS in 2009 is expected to be in excess of $0.40 if exchange rates remain at current levels. Consistent with its year-to-date performance, the Company expects to offset this currency impact by continuing its efforts in supply chain optimization and other operational process improvements.  Based on these sales expectations, continuation of the cost improvement efforts, lower interest rates, an effective tax rate of approximately 30% and exchange rates remaining at current levels, we expect to report 2009 diluted EPS slightly above $2.70, improving on the $2.65 reported for 2008.
  • Management expects net cash provided by operations to exceed $445 million and capital expenditures of approximately $120 million for 2009, raising its free cash flow guidance to an amount in excess of $325 million for the full year, up about 10% from the previous guidance.  


Cash Flow and Debt:  Cash flow from operations for the first nine months of 2009 was $362 million compared to $300 million for 2008.  This change reflects a reduction in working capital, most notably a reduction in inventory of $39 million partially offset by a $23 million tax disbursement in 2009's second quarter due to the timing of international tax payments. Capital expenditures increased to $88 million for the nine months ended September 30, 2009 from $65 million for the same period of 2008 as the Company made investments to expand its biotech capacity in Israel and its manufacturing capacity for viral products and active pharmaceutical ingredients in the U.S. Overall free cash flow of $274 million in the first nine months of 2009 was used to repay $142 million in short-term debt and return $99 million to shareholders through share repurchases and a 12% increase in the 2009 quarterly dividend. The Company's debt to capital ratio was reduced to 25.9% at September 30, 2009 from 34.6% at December 31, 2008.  The Company has not experienced any problem in placing its short-term debt in the current credit market environment.

Share Repurchase:  Another 0.4 million shares were acquired in the third quarter of 2009 at an average share price of $51.65. There were 121.7 million shares outstanding at September 30, 2009. The Company has 6.7 million remaining authorized shares for purchase, but the timing and number of shares purchased, if any, depends upon market conditions and other factors.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, and as key components in pharmaceutical, diagnostic and other high technology manufacturing.  We have customers in life science companies, university and government institutions, hospitals and in industry.  Over one million scientists and technologists use our products.  Sigma-Aldrich operates in 38 countries and has 7,800 employees providing excellent service worldwide.  We are committed to accelerating our Customers' success through leadership in Life Science, High Technology and Service.  For more information about Sigma-Aldrich, please visit our award winning web site at

Non-GAAP Financial Measures: The Company uses certain non-GAAP financial measures to supplement its GAAP disclosures.  The Company does not, and does not suggest investors should, consider such non-GAAP financial measures in isolation from, or as a substitute for, GAAP financial information.  These non-GAAP measures may not be consistent with the presentation by similar companies in the Company's industry.  Whenever the Company uses such non-GAAP measures, it provides a reconciliation of such measures to the most closely applicable GAAP measure.  See the Supplemental Financial Information on pages 8 and 9 for these reconciliations.

With over 60% of sales denominated in currencies other than the U.S. dollar, management uses currency adjusted growth, and believes it is useful to investors, to judge the Company's controllable, local currency performance.  Organic sales growth data presented in this release is proforma data and excludes currency impacts. While we are able to report currency impacts after the fact, we are unable to estimate changes that may occur later in 2009 to applicable exchange rates and are thus unable to reconcile the projected non-GAAP, currency adjusted internal growth rates to reported GAAP growth rates for the year 2009.  Any significant changes in currency exchange rates would likely have a significant impact on our reported growth rates due to the volume of our sales denominated in foreign currencies.

Management reports both GAAP and adjusted sales and income(including EPS) and comparisons to reflect what it believes are ongoing and/or comparable operating results excluding currency impacts.  Management excludes this item in judging its historical performance and in assessing its expected future performance. Management also uses free cash flow (defined on page 7), a non-GAAP measure, to judge its performance and ability to pursue opportunities that enhance shareholder value. Management believes this non-GAAP information is useful to investors as well.  

Cautionary Statement:  This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs, including the "Highlights-Outlook", "CEO's Statement", "2009 Outlook" and "Other Information-Cash Flow and Debt and Share Repurchase" sections contained above and other statements regarding the Company's expectations, goals, beliefs, intentions and the like regarding future sales, earnings, free cash flow, share repurchases, acquisitions and other matters. These statements are based on assumptions regarding Company operations, investments and acquisitions and conditions in the markets the Company serves.  The Company believes these assumptions are reasonable and well founded. The forward looking statements in this release are subject to risks and uncertainties, including, among others, certain economic, political and technological factors. Actual results could differ materially from those stated or implied in this news release, due to, but not limited to, such factors as (1) global economic conditions, (2) changes in pricing and the competitive environment and the global demand for our products, (3) fluctuations in foreign currency exchange rates, (4) changes in research funding and the success of research and development activities, (5) dependence on uninterrupted manufacturing operations, (6) changes in the regulatory environment in which the Company operates, (7) changes in worldwide tax rates or tax benefits from domestic and international operations, including the matters described in Note 4-Uncertainty in Income Taxes-to the Consolidated Financial Statements in the Company's Form 10-Q report for the quarter ended June 30, 2009,  (8) exposure to litigation, including product liability claims, (9) the ability to maintain adequate quality standards, (10) reliance on third party package delivery services, (11) failure to achieve planned cost reductions in global supply chain rationalization, (12) an unanticipated increase in interest rates, (13) failure of planned sales initiatives in our Research and SAFC businesses, (14) other changes in the business environment in which the Company operates, and  (15) the outcome of the matters described in Note 13-Contingent Liabilities and Commitments-to the Consolidated Financial Statements in the Company's Form 10-Q report for the quarter ended June 30, 2009. A further discussion of the Company's risk factors can be found in Item 1A of the Company's Form 10-K report for the year ended December 31, 2008. The Company does not undertake any obligation to update these forward-looking statements.                                    

SOURCE Sigma-Aldrich


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store